Felicity Thomas - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Felicity Thomas's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Felicity Thomas
Verified
European Editor, Pharmaceutical Technology
Cheshire
Beats
mental health advocacy. and mental health educationMental health
I don’t review food/restaurants etc.
Content
By Felicity Thomas Verified, Susan Haigney Verified| BioPharm International Verified Edwin Stone, CEO of Cellular Origins, sees two themes having the biggest impact to the bio/pharma industry: the expansion of glucagon-like peptide-1 (GLP-1) and the growth of cell therapies from fourth- and third-line treatments to second-line treatments. “It really opens up that question of, when do we start to see first line treatments? And of course, part of that comes down to not just the safety and efficacy profiles, but the cost of goods, which still no one has a good answer to,” Stone says.
Ask the Expert: Product Inspection, Part Two; Automated Product Inspection and Cold Chain Considerations
By Felicity Thomas Verified, Susan Haigney Verified| BioPharm International Verified In this episode of Ask the Expert, Dirk Margosch, Vice President Visual Inspection, Assembly & Secondary Packaging at Vetter Pharma-Fertigung GmbH & Co KG, addresses the benefits of automating visual inspection, which include increased efficiency and accuracy, and what goes into the cost versus benefit of automating inspection of small batches. “[T] he decision to continue manual inspection for small batch sizes involves several considerations,” says Margosch.
By Felicity Thomas Verified, Susan Haigney Verified| BioPharm International Verified Edwin Stone, CEO of Cellular Origins, sees two themes having the biggest impact to the bio/pharma industry: the expansion of glucagon-like peptide-1 (GLP-1) and the growth of cell therapies from fourth- and third-line treatments to second-line treatments. “It really opens up that question of, when do we start to see first line treatments? And of course, part of that comes down to not just the safety and efficacy profiles, but the cost of goods, which still no one has a good answer to,” Stone says.
Company Info
Pharmaceutical Technology
Medical Device Network is an industry information platform focused on the medical device sector. It provides news, analysis, and directories related to medical device supply chains, regulatory issues, and market trends. The platform serves as a resource for professionals in the industry, offering insights and listings of medical device manufacturers and service providers. Its revenue model likely includes advertising and lead generation through company profiles and sector reports.
London, United Kingdom
+1 646-625-7388